Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Treatment of antibody-mediated post-transplant autoimmune-like pepatitis with daratumumab

Akshay Sharma • 2 Feb 2021
TCT 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Daratumumab

Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, presents a case study of the use of daratumumab, an anti-CD38 monoclonal antibody, for post-transplant autoimmune-like hepatitis in a patient with B-cell acute lymphoblastic leukemia who underwent hematopoietic cell transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

1:45
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Akshay Sharma • 12 Dec 2022
1:44
Phase II study of MGTA-145 in combination with plerixafor for HSC mobilization in patients with SCD
Akshay Sharma • 12 Dec 2022
0:56
Treatment of severe SCD with OTQ923 CRISPR/Cas9 gene therapy
Akshay Sharma • 12 Dec 2022
2:43
A machine learning model to improve outcome prediction following allogeneic transplantation
Akshay Sharma • 12 Dec 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals